Buparlisib and the continued quest for the ideal cure
Mené sur 158 patients atteints d'un carcinome épidermoïde de la tête et du cou récidivant ou métastatique, cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du buparlisib à un traitement par paclitaxel, après l'échec d'un traitement à base de sels de platine
In metastatic or recurrent squamous cell carcinoma of the head and neck, the choice of systemic therapy should be individualised, based on patient characteristics, tolerability of treatment, and goals of therapy. When patients do not respond to definitive therapies, their disease carries a poor prognosis with a median survival overall survival of less than 1 year. In this setting, the standard of care has become treatment with cetuximab and platinum with fluorouracil.1 If patients do not respond to platinum therapy, overall response and survival remain dismal even in the face of two immunotherapy checkpoint inhibitors, pembrolizumab and nivolumab, approved in the past 6 months.
The Lancet Oncology , commentaire, 2016